Actively Recruiting
END - VT Cohort Study
Led by Nova Scotia Health Authority · Updated on 2024-07-16
2454
Participants Needed
3
Research Sites
276 weeks
Total Duration
On this page
Sponsors
N
Nova Scotia Health Authority
Lead Sponsor
M
Maritime Heart Centre
Collaborating Sponsor
AI-Summary
What this Trial Is About
Ventricular tachycardia (VT) is a life-threatening cardiac rhythm disturbance which leads to sudden cardiac death (SCD), ventricular fibrillation, electrical storm, hemodynamic collapse, and syncope. VT patients with cardiomyopathy (diseased/scarred cardiac muscle) have the highest risk of SCD (\<1-4%) and recurrent VTs (15-35%). Although an implantable cardiac defibrillator (ICD) is the most effective treatment option to prevent SCD, it does not eliminate it. Without VT prevention, recurrent VT and ICD shocks may increase the risk of heart failure and death. The primary objective is to determine the optimal treatment strategy to maximize event-free survival among cardiomyopathy patients with ventricular tachycardia (VT) by the creation of a prospective, multicenter, longitudinal cohort. Also, the investigators will evaluate the epidemiology of VT, adherence to guidelines, safety, effectiveness, and cost-effectiveness of current treatment options for secondary prevention of VT in the real-world Canadian VT population.
CONDITIONS
Official Title
END - VT Cohort Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Documented sustained ventricular arrhythmia lasting more than 30 seconds as shown by ECG, cardiac monitor, AED, or ICD electrograms
- First-time (new) diagnosis of ventricular tachycardia
- Have or plan to have an implantable cardiac defibrillator (ICD) placed during current hospitalization
- Diagnosis of cardiomyopathy such as ischemic, hypertrophic, dilated, restrictive, arrhythmogenic, or other scar-related types
- Planned follow-up care at an ICD clinic
- Age greater than 18 years old
You will not qualify if you...
- Ventricular tachycardia caused by a reversible condition
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Providence Health Care Society
Vancouver, British Columbia, Canada
Actively Recruiting
2
QEII Health Science Centre
Halifax, Nova Scotia, Canada, B3H3A7
Actively Recruiting
3
Montreal Heart Institute,
Montreal, Quebec, Canada, H1T 1C8
Actively Recruiting
Research Team
J
John L Sapp, MD, FRCPC
CONTACT
S
Suzanne E Greeley, BSCN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here